Aims: To assess the prognostic significance of apoptosis related markers in bladder cancer. Methods: A tissue microarray containing 179 bladder carcinomas from cystectomy specimens was analysed immunohistochemically for active caspase-3, single-stranded DNA (ssDNA), p53, Scl-2, Sax, and COX-2, in correlation to clinicopathological factors. Results: Active caspase-3, ss DNA, p53, Sax and COX-2 were more frequently observed among high grade and higher stage (2: T2) carcinomas compared with low grade and lower stage (T1) tumours. On the contrary, Scl-2 was more frequently detected in T1 than in 2: T2 carcinomas. Active caspase-3 correlated with a better survival of the patients. Conclusions: The decreased detection of active caspase-3 and ssDNA and the increased presence of Scl-2 in T1 carcinomas suggest that alterations in interrelated apoptosis markers may play an important role in the progression of urothelial carcinoma from a superficially infiltrating to a muscle invading tumour and would help to better characterise a subpopulation of T1 carcinomas that could profit from early cystectomy or more aggressive adjuvant chemotherapy. Active caspase-3 might be an important prognostic factor in bladder cancer.
INTRODUCTION
Genetic changes affecting proliferation and apoptosis contribute to the development of urothelial carcinoma. 1-.1 Alterations in gene products regulating apoptosis in bladder cancer cells like pS3, BcI-2 and Bax are associated with decreased apoptotic cell death and increased cell survival 4 . 5 The morphological changes of apoptosis are mediated by a group of cysteine proteases, the caspases. Caspases play an essential role in the initiation, regulation and execution of apoptosis. 6 -8 Particularly, caspase-3 is required for cleavage of a large number of proteins and of nuclear collapse during apoptosis. 9 Similarly, DNA fragmentation is observed in all nucleated cells. The immunohistochemical detection of active caspase-3 and single-stranded DNA (ssDNA) therefore could represent a valuable tool for the identification of apoptotic cells in tissue sections. to. 1 t
In the present study we employed immunohistochemistry for active caspase-3 and ssDNA for the detection of apoptosis in 179 bladder carcinomas from cystectomy specimens combined in a tissue microarray (TMA). The results were compared with the expression of proteins involved in the modulation of apoptosis, such as pS3, BcI-2, Bax, and COX-2, and were correlated to the stage of the disease, and the clinical outcome.
MATERIALS AND METHODS

Patients and specimens
Formalin-fixed, paraflin-embedded radical cystectomy specimens rrom 179 patients (129 males and 50 remales; mean age 67 years, range 35 86 years) with invasive urothelial carcinoma or the bladder, and 42 normal controls were used. According to the sixth edition or the TNM classification or malignant tumours, the 179 tumours included 17 pTI, 26 pT2, 103 pT3 and 33 pT4 cases. J2 Lymph node metastases were present in 39 patients (22%). According to the 2004 World Health Organization (WHO) and International Society or Urological Pathology (ISUP) classification , the majority or the tumours (i.e. , 169) were WHO high grade while 10 tumours were low grade. I.! Construction of tissue microal'ray (TMA) TMA was built as previously described.'" Briefly, one core tissue biopsy with a diameter or 0.6 mm was taken rrom a representative region or individual paraffin embedded bladder carcinomas (donor blocks) and placed into a new recipient paraffin block using a semi-automated tissue arraying device . The presence or tumour ti ssue on the TMA was verified on a haematoxylin and eosin (H&E) stained slide. Two to three tissue cores or each tumour were available for biomarker ana lys is. Five ~lm sections were c ut using an adhesive-coated slide system (Instrumedics , USA) and examined by immunohistochem istry. The number or samples varied slightly be tween the individual mark ers beca use or variabi lity in the number or interpretable specimens on TMA sections.
Assessment of behaviour
Medical charts were available rrom 175 patients (98% ; 126 males a nd 49 remales). or these, 8 1 (46.28%) died or the disease, and 59 (33.7%) were alive wi th out recurrent/ metastatic disea se. An additional 35 patients (20"!.J) died or o ther causes. M ea n rollow-up was 57 months (median 40; range I 200; SO 49.8).
Immunohistochemistry
TMA section s were deparallinised , rehydrated and pretreated for 10 min in 10 mM citrate pH 6.0 in a pressure cooker. They were then incubated with the following primary antibodies: anti-active caspase-3 (1: 100; Bio-concept, USA), anti-ssDNA (clone F7-26, 10 Ilg/mL, Apostain; Alexis Biochemicals, USA), p53 (clone DO-7 , 1:200; Novocastra, UK) , BcI-2 (clone 124, 1 :200; DakoCytomation, Denmark), Bax (clone 2D2, 1: 100; Neomarkers , USA) and COX-2 (clone CX294, 1:25; DakoCytomation) according to the manufacturers' protocols. In negative contro ls the primary antibody was replaced with an irrelevant, isotype-matched antibody. As positive con trol , sections from a TMA with many different samples of normal tissue were sta ined in parallel.
Scoring of immunohistochemistry
T he scoring was performed by a stafr pathologist with expertise in genitourinary pathology who was blinded to clinical outcome and stage of the tumours. 
Statistical analysis
Kaplan Meier plots were used to estimate overall survival from cystectomy to the date of death from any ca use or to the date of relapse. Difierences among subgroups were assessed using the log-rank test. Significance level was set at p < 0.05.
Kendall's Tau-b was used to measure the correlation coeflicient of the expression of immunohistochemica l markers to the histologica l parameters and stage of tumours. The levels of significance were determined by a twotailed test.
RESULTS
Fig.
shows typical examples of active caspase-3 ( Fig. lA,B ) and ssONA staining (Fig. lC,D Active caspase-3 was detected in the cytoplasm of cells showing typical apoptotic morphology (Fig. lA,B) . No positive staining was observed in areas of necrosis or in normal urothelium . Positive reaction for caspase-3 was found in 45.34% of tumours (Table I) .
Active caspase-3 positive cells were significantly more frequent in high grade compared with low grade carcinomas (p = 0.024; Fig. 3A ). In addition, active caspase-3 immunoreactivity was more frequently present in pT2 or higher stage tumours as opposed to pTl carcinomas (p = 0.044), and was more often detected in nodal positive (62.8%) compared with nodal negative carcinomas (40.5%) ( Table 2) ; however, this difference was not statistically significant.
ssONA immunoreactivity was present in 39.4% of tumours. Most positive cells exhibited a nuclear staining. The number of samples varied between the individual markers because of differences in the number of the interpretable tumour specimens o n tiss ue microarray sections. In some cells also a cytoplasmic staining was noted, most likely reflecting the release of ssDNA into the cytoplasm (Fig. I C,D) . Areas of tumour necrosis and normal urothelium remained immunonegative. Muscle invading tumours (i.e., 2: pT2) showed an increased number of ssDNA positive cells (41 %) compared with pTI carcinomas (23%; p = 0 .979). Positive nuclear p53 staining was observed in 61.7% of tumours and correlated significantly with the T -s tage, being found in 30.7% of pTI compared with 64% of 2:pT2 carcinomas (p = 0.049; Table I ; Fig. 2A) . Moreover, p53 immunoreactivity was significantly more frequent in high grade as opposed to low grade carcinomas (p = 0.018; Fig. 3B ).
Positive cytoplasmic immunoreactivity for BcI-2, COX-2 and Bax was seen in 7.5%, 36.8% and 50.3% of tumours, respectively ( Fig. 2A-D) . COX-2 was significantly more frequently found in high grade as opposed to low grade neoplasms (p = 0.0 19; Fig. 3C ). COX-2 and Bax were more often found in higher stage neoplasms exhibiting immunopositive reaction in 0% and 23% of pTI compared with 40.4% and 51.7% of 2:pT2 carcinomas, respectively. In contrast, BcI-2 immunoreactivity was more common ly found in pTI tumours (23%) than in the muscle invading tumours (9.5%; Table I ). COX-2 expression correlated significantly with the presence of active caspase-3 (p = 0.03).
Correlation with survival
The presence of active caspase-3 correlated with a better survival in this series, since patients with active caspase-3 positive tumours survived I year longer than patients with active caspase-3 negative carcinomas (p = 0.0260; Fig. 4A ). The presence of ssDNA did not correlate with survival.
The presence of low p53 immunoreactivity (i.e., 10-20%) correlated with a better survival in all patients as well as in patients dying of bladder cancer after cystectomy, compared with absence of (i .e., < 10%) or high (i .e., >20%) p53 immunoreactivity (p = 0.0124; Fig. 4B, C) .
No correlation between BcI-2, Bax and/or COX-2 and survival of the patients was noted.
DISCUSSION
While current histopathological criteria can provide important morphological information about tumour stage and grade, they have clear limits in specifying the risk of progression or response to treatment for an individual patient with urothelial carcinoma. ls Definition of individual prognostic markers is mandatory for a standardised and optimised therapy.1 6 Apoptotic cell death is as important as cell proliferation for tumour growth.
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Therefore, the detection of apoptosis in situ and its correlation with the expression of pro-and an ti-apoptotic molecules seems to be worth further evaluation. In this study we evaluated active caspase-3 and ssDNA for the detection of apoptosis in bladder cancer in correlation to clinicopathological factors.
Active caspase-3 immunoreactivity correlated with unfavourable histological parameters such as high grade and advanced stage of tumours. This finding is in agreement with a previous report l 8 which showed that overexpression of activated caspase-3 was associated with a high chance of disease invasiveness. Although this may appear contradictory at first glance, there are numerous reports that link deregulated cell cycle progression with induction of apoptosis. For example, the oncogene c-Myc, often overexpressed in tumour cells, promotes cell proliferation, but may also induce apoptosis in the absence of suflicient survival signals. 19 Since advanced tumours frequently show impaired histological differentiation, we assume our observation in the context of an increased cellular turnover . . that results in a higher rate of apoptosis. However, active caspase-3 immunoreactivity correlated significantly with a better survival of the patients (p < 0.05; Fig. 3A ). This finding indica tes that active caspase-3 might be an important prognostic factor for bladder cancer and could be attributed to an increased rate of apoptotic cell death leading to accelerated tumour involution. Moreover, it could be hypothesised that active caspase-3 positive tumours would be more susceptible to induction of apoptotic cell death by chemotherapeutic agents compared with active caspase-3 negative, apoptosis resistant neoplasms. Our findings are Rartly in agreement with those of Kara m and co-workers 2 ) who also showed that altered apoptosis markers constitute an important prognostic indicator for patients with bladder cancer.
Our study also revealed that active caspase-3 and ssDNA are not equally sensitive in detecting apoptotic cells in urotheli al carcinoma. This may be attributed to different reasons. Caspase-3 activation represents an early and central step in apoptotic pa thway. In contrast, DNA degrada tion occurs later and is often dependent on caspase-3 activation.
2 1 Moreover, la te apoptotic cells exhibiting DNA degradation are often removed by phagocytes and are therefore more difficult to detect. This could also partly explain the fact that ssDNA positivity, in contrast to active caspase-3, did not have any influence on the survival of the pa tients.
p53 is a transcription factor that can induce the expression of multiple pro-apoptotic gene products, including caspase activators. 22 In the present study, p5 3 immunoreactivity correlated significantly with increased tumour stage (p < 0.05 ; Table I ) and caspase-3 positivity (p = 0.013). Moreover, p53 staining was associated with decreased overall survival of the pa tients. However, the presence of low p53 immunoreactivity (i .e., 10-20%) correlated with a better survival in all patients as well as in patients dying of bladder cancer after cystectomy, compared with absence of (i.e., < 10%) or high (i .e., > 20%) p53 immunoreactivity (Fig. 38) . Absence of p53 immunoreactivity is likely the result of either degraded p53 or deletion of the p53 gene. Clearly this results in impaired functions of this tumour suppressor gene and reduced apoptosis in response to DNA damaging agents a nd thereby to reduced survival of the patients. In contrast, low p53 immunoreactivity could be attributed to the presence of wild-type p53, which may have maintained its normal tumour suppressor functions , thus trigge ring apoptosis and being associated with better survival of the patients. Finally, hi gh immunoreactivity in the absence of increased survival of the patients may be associated with hi gh expression of a muta ted form of p53 incapable of activating apoptosis pathway and thereby executing the tumo ur suppressor function s of p53 . Previous studies 2 .\. 24 showed considerable ditTerences concerning the prognostic significance of p53 tumour status in bladder cancer, which was a ttributed to the di fferent p53 immunohistochemistry protocols used, patient selection and study design. Our findin gs suggest that some of the differences may be related to quantitative differences in p53 expression of the tumour cells.
The 8cl-2 family of proteins is known to play a pivotal role in the regulation of apoptosis. 25 In our study, 8cl-2 was more frequently expressed in lower stage tumours that were mostly caspase-3 and ssDNA negative. This finding is compatible with the anti-apoptotic function of 8cl-2. On the contrary, 8ax immunoreactivity was more often present in higher stage tumours, frequently showing active caspase-3 and ssDNA positivity, supporting a proapoptotic function of this protein .
A further factor conferring resistance to a poptosis is cyclooxygenases. 26 Previous studies 27 showed that COX-2 correla ted with local invasion, Iymphovascula r invasion and recurrence in bladder carcinomas. In our study COX-2 immunoreactivity was strongly associated with mu scle invasion , and correlated significantly with the presence of active caspase-3 (p = 0.03).
Our results show that apoptotic cell death, as assessed by active caspase-3 and ssDNA immunohistochemical detection, is a common finding in bladder cancer. The decreased expression of active caspase-3 and ssDNA and the increased presence of 8cl-2 in the pTI carcinomas sugges t that alterations in interrelated apoptosis markers may play an important role in the progression of urothelial carcinoma from a superficially infiltrating to a muscle invading tumour. Since it is known tha t pTI bladder carcinomas represent a heterogeneous group of tumours, this findin g might help to better characterise a subpopulation of pTI carcinomas that could profit from early cystectomy or aggressive chemotherapy. The presence of active caspase-3 immunoreactivity correlated with better survival of the patients indicating that active caspase-3 might be a relevant prognostic factor for patients with bladder cancer.
